These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

66 related articles for article (PubMed ID: 7853725)

  • 21. [Effect of a clofibrate-inositol nicotinate combination on lipids and lipoproteins in primary hyperlipoproteinemia of types IIa, IV and V].
    Hutt V; Wechsler JG; Klör HU; Ditschuneit H
    Arzneimittelforschung; 1983; 33(5):776-9. PubMed ID: 6683558
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The development of resistance to a potent lipolysis inhibitor, 3-methylisoxazole-5-carboxylic acid.
    Pereira JN; Holland GF
    J Pharmacol Exp Ther; 1967 Aug; 157(2):381-7. PubMed ID: 6039829
    [No Abstract]   [Full Text] [Related]  

  • 23. Management of hyperlipidemia: goals for the prevention of atherosclerosis.
    Illingworth DR
    Clin Invest Med; 1990 Aug; 13(4):211-8. PubMed ID: 2208837
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Clofibrate therapy--the status quo].
    Reuter W
    Z Gesamte Inn Med; 1982 Jan; 37(2):59-63. PubMed ID: 7080553
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Insulinemia, fatty acids in plasma lipids and lipoproteins and oxidation of VLDL and LDL in hyperlipidemia].
    Zeman M; Zák A; Tvrzická E; Buchtíková M; Stípek S; Pousek L
    Sb Lek; 2000; 101(1):77-82. PubMed ID: 10953635
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pathogenic role of abnormal fatty acids and adipokines in the portal flow. Relevance for metabolic syndrome, hepatic steatosis and steatohepatitis.
    Brudaşcă I; Cucuianu M
    Rom J Intern Med; 2007; 45(2):149-57. PubMed ID: 18333368
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Regulation of plasma triglycerides in insulin resistance and diabetes.
    Ginsberg HN; Zhang YL; Hernandez-Ono A
    Arch Med Res; 2005; 36(3):232-40. PubMed ID: 15925013
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Treatment of hyperlipoproteinemia type II with etofibrate.
    Gustafson A
    Int J Clin Pharmacol Biopharm; 1979 Dec; 17(12):498-502. PubMed ID: 528096
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effectiveness of low-dose crystalline nicotinic acid in men with low high-density lipoprotein cholesterol levels.
    Martin-Jadraque R; Tato F; Mostaza JM; Vega GL; Grundy SM
    Arch Intern Med; 1996 May; 156(10):1081-8. PubMed ID: 8638995
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Nocturnal inhibition of lipolysis in man by nicotinic acid and derivatives.
    Kruse W; Kruse W; Raetzer H; Heuck CC; Oster P; Schellenberg B; Schlierf G
    Eur J Clin Pharmacol; 1979 Aug; 16(1):11-5. PubMed ID: 499296
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Modification of nicotinic acid and prostaglandin E1 antilipolytic action in vitro.
    Sutherland WH; Larking PW; Nye ER
    Atherosclerosis; 1976 Oct; 25(1):45-53. PubMed ID: 186078
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effects of nicotinic acid and its derivatives on lipid metabolism and other metabolic factors related to atherosclerosis.
    Walldius G; Wahlberg G
    Adv Exp Med Biol; 1985; 183():281-93. PubMed ID: 4036701
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Lipoprotein metabolism and atherogenesis: implications for therapy.
    Kostner GM
    Cardiology; 1991; 78(3):194-201. PubMed ID: 1651161
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pharmacological profile of a new anti-lipolytic agent: 5-methyl-pyrazine-2-carboxylic acid 4-oxide (acipimox) (1) I - Mechanism of action.
    Lovisolo PP; Briatico-Vangosa G; Orsini G; Ronchi R; Angelucci R; Valzelli G
    Pharmacol Res Commun; 1981 Feb; 13(2):151-61. PubMed ID: 6261266
    [No Abstract]   [Full Text] [Related]  

  • 35. Mechanisms of lipid-lowering agents.
    Sirtori CR; Manzoni C; Lovati MR
    Cardiology; 1991; 78(3):226-35. PubMed ID: 1868500
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Plasma lipids and urinary excretion of catecholamines in man during experimentally induced emotional stress, and their modification by nicotinic acid.
    Carlson LA; Levi L; Orö L
    J Clin Invest; 1968 Aug; 47(8):1795-805. PubMed ID: 5666111
    [TBL] [Abstract][Full Text] [Related]  

  • 37. 5-(3-pyridyl)tetrazole, a potent and long-acting lipolysis inhibitor.
    Holland GF; Pereira JN
    Experientia; 1967 Feb; 23(2):88-9. PubMed ID: 6040484
    [No Abstract]   [Full Text] [Related]  

  • 38. Nicotinic acid and inhibition of fat mobilizing lipolysis. Present status of effects on lipid metabolism.
    Carlson LA
    Adv Exp Med Biol; 1978; 109():225-38. PubMed ID: 364948
    [No Abstract]   [Full Text] [Related]  

  • 39. Effect of nicotinic acid on ACTH and noradrenaline stimulated lipolysis in the rabbit. I. In vivo studies.
    Boberg J; Micheli H; Rammer L
    Acta Physiol Scand; 1970 Jun; 79(2):153-7. PubMed ID: 4318364
    [No Abstract]   [Full Text] [Related]  

  • 40. Experimental studies on the hypolipidemic activity of chloridarol.
    Bernini F; Musanti R; Trezzi E; Corsini A; Fumagalli R; Meldolesi J; Catapano AL
    Pharmacol Res Commun; 1983 Feb; 15(2):201-15. PubMed ID: 6844377
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.